# Orchard Venture Partners

> Orchard Venture Partners is a VC fund backing Biotechnology and Health Care. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Chicago, United States
- Total investments: 10
- Last investment: Feb 2022
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/orchard-venture-partners
- Website: http://www.ocvpartners.com

Orchard Venture Partners (formerly Sigvion Capital) is a life sciences venture capital firm that was founded in 2004. The firm invests in tangible scientific assets, moves them through clear clinical milestones, and sells to innovation-hungry large medical companies.The confluence of technology and biology has created world-changing medicalopportunities. At the same time market conditions have created compelling investment opportunities.Supply: Early-stage valuations have rarely been as attractive. Demand: Demand for mid- to late-stage products is reaching new highs. Major medical companies are in dire need of new products as the last generation’s blockbusters reach the end of their patent lives.Orchard systematically moves assets from early-stage to mid- or late-stage; focusing on tangible scientific assets, clear value-adding milestones, business execution, and capital efficiency.

## Contacts

5 contacts available for Orchard Venture Partners. Shizune tracks 3 team members at Orchard Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sigvion-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 50% |
| Health Care | 4 | 40% |
| Therapeutics | 4 | 40% |
| Life Science | 2 | 20% |
| Energy | 1 | 10% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 30% |
| Series A | 2 | 20% |
| Grant | 1 | 10% |
| Series C | 1 | 10% |
| Funding Round | 1 | 10% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 60% |
| United Kingdom | 1 | 10% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Richard Ressler | President and Founder | 0 | https://shizune.co/investors/profile/richard-ressler |
| Josh Fairbank | Founding Partner | 0 | https://shizune.co/investors/profile/josh-j-p-fairbank |
| Michael E. Pape | Partner | 0 | https://shizune.co/investors/profile/michael-e-pape |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Verlume | Verlume designs and supplies subsea battery and power-management systems for offshore and underwater applications. Its product portfolio includes modular “Charge” batteries (35/55 kWh), large-scale “Halo” systems (100 kWh to MWh), and “Orah” units for very large capacity needs. At the heart of its offerings is Axonn, a platform that enablesautonomous decision making, power control of intermittent sources, health monitoring, and communications gateway capabilities. Verlume works with clients in sectors such as offshore wind, ocean science, monitoring, and oil & gas to deliver intelligent energy solutions in harsh subsea environments. | $3.4M | Venture - Series Unknown | Feb 02, 2022 |  |
| GUIDEcx | GuideCX offers everything you need to provide a self-serve implementation experience in one versatile and dynamic package. Use templates to automate and reproduce repetitive processes that involve customers and 3rd parties. (i.e. Onboarding, Procurement...). Automated communication provides updates and maintains accountability. By improving theefficiency and transparency of the onboarding process, you can do more with less when you use GuideCX. | $10M | Series A | Nov 12, 2020 |  |
| Verlume | Verlume designs and supplies subsea battery and power-management systems for offshore and underwater applications. Its product portfolio includes modular “Charge” batteries (35/55 kWh), large-scale “Halo” systems (100 kWh to MWh), and “Orah” units for very large capacity needs. At the heart of its offerings is Axonn, a platform that enablesautonomous decision making, power control of intermittent sources, health monitoring, and communications gateway capabilities. Verlume works with clients in sectors such as offshore wind, ocean science, monitoring, and oil & gas to deliver intelligent energy solutions in harsh subsea environments. | $2M | Venture - Series Unknown | Apr 20, 2020 |  |
| Akebia Therapeutics | Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolylhydroxylase enzyme and phosphatase enzyme. Akebia Therapeutics, Inc. was founded in 2007 and is based in Cincinnati, Ohio. | $41M | Series C | Jun 04, 2013 |  |
| Akebia Therapeutics | Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolylhydroxylase enzyme and phosphatase enzyme. Akebia Therapeutics, Inc. was founded in 2007 and is based in Cincinnati, Ohio. | $22M | Series B | Apr 26, 2011 |  |
| Base4 Biotechnology | Nymirum is a venture-backed, privately held company that has developed the RNArchitect suite to rapidly solve high-resolution RNA 3D structures and a proprietary drug discovery platform that targets RNA with small molecules. | $2.8M | Grant | Jan 01, 2010 |  |
| Akebia Therapeutics | Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolylhydroxylase enzyme and phosphatase enzyme. Akebia Therapeutics, Inc. was founded in 2007 and is based in Cincinnati, Ohio. | $25M | Series A | Jul 28, 2009 |  |
| Logical Therapeutics | Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulationof normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts. | $30M | Series B | Jun 13, 2007 |  |
| Kereos | Kereos, Inc., a biotechnology company, develops targeted molecular imaging agents and therapeutics to detect and treat cancer and cardiovascular disease. The company offers KI-0001, a magnetic resonance imaging (MRI) agent for tumor detection that finds tumors and highlights growing regions in the tumor margin; and KI-100X, a targetedchemotherapeutics for solid tumors, which reduces angiogenesis in tumor and atherosclerosis models, as well as inhibits tumor growth. It also provides KI-0002, an MRI agent for cardiovascular disease detection via an undisclosed biomarker; KI-1004, an anti-restenotic that inhibits restenosis while preserving re-endotheliazation in angioplasty models; and KM-4419, a targeted chemotherapeutic for solid tumors that synergizes with several chemotherapeutics in blocking tumor growth and increasing survival. In addition, the company works with pharmaceutical and imaging companies for the development and commercialization of cardiovascular disease MRI agents, as well as development of molecular imaging systems. Kereos, Inc. was founded in 1999 and is based in St. Louis, Missouri. | $19.5M | Series B | Sep 20, 2005 |  |
| Sierra Oncology | Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. The company harnesses its deep scientific expertise to identify compounds that target the root cause of disease. Sierra Oncology's team takes an evidence-based approach to understand the limitations of currenttreatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact. | $1.1M |  | Mar 14, 2005 |  |

10 of 10 investments shown.

## Co-investors
- [Triathlon Medical Venture Partners](https://shizune.co/investors/profile/triathlon-medical-venture-partners) — VC Fund, 4 deals together
- [Venture Investors](https://shizune.co/investors/profile/venture-investors) — VC Fund, 3 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 2 deals together
- [Par Equity](https://shizune.co/investors/profile/par-equity) — VC Fund, 2 deals together
- [Album VC](https://shizune.co/investors/profile/album) — VC Fund, 1 deal together
- [Apjohn ventures](https://shizune.co/investors/profile/apjohn-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Life Science Investors in Canada](https://shizune.co/investors/life-science-investors-canada)

## FAQ

### What does Orchard Venture Partners invest in?

Orchard Venture Partners invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Orchard Venture Partners?

Public channels for Orchard Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Orchard Venture Partners?

The team at Orchard Venture Partners includes Richard Ressler (President and Founder), Josh Fairbank (Founding Partner) and Michael E. Pape (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co